甲型H1N1流感治疗新药扎那米韦  

A new drug for the treatment of influenza A(H1N1)——zanamivir

作　　者：赵绪韬[1] 周新[2] 

机构地区：[1]上海医药工业研究院信息中心,上海200040 [2]上海交通大学附属第一人民医院呼吸科,上海200080

出　　处：《世界临床药物》2009年第12期705-707,714,共4页World Clinical Drug

基　　金：科技部"重大新药创新"科技重大专项资助(项目编号:2009ZX09309)

摘　　要：世界卫生组织(WHO)专家警示,2009年秋冬季可能出现甲型H1N1流感大规模暴发。葛兰素史克公司研发生产的神经氨酸酶抑制剂——扎那米韦吸入粉雾剂(zanamivir,依乐韦,Relenza)能有效治疗甲型和乙型流感,是WHO和美国疾病控制与预防中心(CDC)指南推荐的抗流感病毒药物,目前分离自临床的甲型H1N1流感病毒尚未见对该药耐药者。其在国内的成功上市,将进一步完善我国应对流感的防控措施。Experts from World Health Organization(WHO) warned that a pandemic influenza(H1N1)might break out in autumn and winter of 2009.Neuramidinase inhibitor—zanamivir(Relenza,GlaxoSmithKline) is effective against influenza A and B,and is recommended as anti-influenza virus treatment in the guidelines instituted by WHO and US Centers for Disease Control(CDC).The entering of Relenza in domestic market will improve our prevention and control of influenza.

关 键 词：甲型H1N1流感 扎那米韦 疗效 安全性 

分 类 号：R978.7[医药卫生—药品]